H19 and non-small cell lung carcinoma: H19 is highly expressed in exosomes derived from breast and non-small cell lung cancer (NSCLC) cells, and depletion of H19 with small interfering RNAs (siRNAs) restored doxorubicin and gefitinib sensitivity to drug-resistant cells of each of these cancer types, respectively [57,58].